一区久久久av青青草原_国产三级在线观看一区_亚洲综合国产一区二区三区_国产一在线精品一区在线观看_亚洲国产韩国欧美在线

山東省眼科醫(yī)院史偉云院長就世界首個SFDA批準的生物工程角膜相關臨床問題，接受了哥倫比亞電視臺的專訪。專訪以《Scientists?working?on?restoring?human?sight?with?pig?eyes》為題在哥倫比亞電視臺播出后，引起了極大反響。
? 史偉云院長詳細介紹了世界首個SFDA批準的生物工程角膜臨床應用情況：“生物工程角膜是由異種角膜經脫細胞特殊工藝的多級處理，去除了角膜中的細胞、雜蛋白、多糖等抗原，保留了天然角膜基質膠原蛋白結構及透明性，生物相容性好，生物安全性高，能與周圍組織快速整合，移植角膜透明，患者視力快速恢復。這是擁有完整自主知識產權的高科技劃時代產品。”
? 同時史偉云院長強調：“人工生物角膜與捐獻人角膜在移植手術技術上有著明顯的特點，不論從手術適應癥選擇到圍手術期處理都有著獨特的技巧，因此生物工程角膜移植手術醫(yī)師培訓是角膜盲患者復明的不可或缺的關鍵因素。”
在山東省眼科醫(yī)院工作人員的引導下，經過消毒等程序，采訪組部分人員獲得允許進入手術室對史偉云院長使用組織工程角膜進行角膜移植手術進行拍攝，史偉云院長精湛的手術技術讓從事多年醫(yī)療采訪的哥倫比亞電視臺記者十分驚訝，連連稱贊：“觀看史院長做手術就像在欣賞一場精彩的演出。”
? 采訪期間，史偉云院長詼諧的說：“你們哥倫比亞電視臺因為臺標像眼睛，所以在美國也被稱作‘眼睛臺’，這跟我們眼科有很深的淵源啊。”史院長的詼諧引讓采訪氣氛格外輕松。
? 哥倫比亞電視臺記者還對已經接受過生物工程角膜移植的患者進行了采訪。

? 相關資料：
? 以山東省眼科研究所、山東省眼科醫(yī)院謝立信院士和泰山攀登計劃特聘專家史偉云教授帶領的學術團隊是中國再生醫(yī)學國際公司研發(fā)的全球首個生物工程角膜技術支持的主要力量。該生物角膜于2015年4月底獲得國家食品藥品監(jiān)督管理總局頒發(fā)的醫(yī)療器械注冊證書，2015年5月23日正式投產上市。作為全球首個生物工程角膜，可廣泛應用于50%的角膜盲治療，將極大地緩解我國捐獻角膜奇缺的臨床困境，為我國400萬乃至全球6000萬的角膜盲患者帶來復明的希望。2015年9月上市后的世界首例生物工程角膜臨床移植在山東省眼科研究所（青島眼科醫(yī)院，山東省眼科醫(yī)院）獲得成功。??
? 鑒于山東省眼科研究所在角膜研發(fā)中的巨大貢獻和在全國角膜病基礎與臨床研究領域的龍頭地位，首個生物工程角膜手術醫(yī)生培訓基地已在山東省眼科醫(yī)院建立。2016年7月至今已培訓近300名國內學員，十余位國際學員，培訓班使學員們對生物工程角膜有了更加深刻的認識，同時提高了臨床實踐能力與手術技能，為更好從事角膜病防治工作奠定了理論與實踐基礎。

史偉云教授簡介：

眼科學博士，二級教授、主任醫(yī)師，博士生導師。中華醫(yī)學會眼科學分會常委、專家會員，中華醫(yī)學會眼科學分會角膜病組組長，《中華眼科雜志》副總編輯及其他8個眼科雜志編委。現(xiàn)任山東省眼科研究所黨委書記、所長、山東省眼科醫(yī)院院長。國務院特殊津貼專家、山東省泰山崗位攀登計劃特聘專家、省有突出貢獻的中青年專家和山東省首屆醫(yī)學領軍人才。在臨床工作方面，具有豐富的臨床經驗和嫻熟的顯微手術技巧，能熟練完成各類眼前段手術，如抗青光眼、白內障超聲乳化摘除聯(lián)合人工晶體植入和各種眼科屈光手術等，尤其在角膜移植術手術方面具有較高的造詣，能夠熟練進行各類復雜的角膜移植術，已累計完成近萬例?？蒲薪虒W方面，作為課題負責人或主要人員共承擔科研課題?20?余項，獲得國家發(fā)明專利?4?項。其中作為負責人承擔國家?863?重大課題、973?重大專項、國家自然科學基金重點項目和面上項目、山東省自然科學基金及省攻關課題等。發(fā)表論文?258?篇、其中?SCI?收錄?53?篇，第一和通訊作者在（PNAS、Ophthalmology）等?SCI?收錄31篇，人民衛(wèi)生出版社出版我國首部《角膜手術學》和《角膜病學》學術專著，獲國家科技進步二等獎兩項和為首獲山東省科技進步一等獎兩項。
? 哥倫比亞電視臺簡介：

美國哥倫比亞電視臺，是美國五大電視臺之一，是具有巨大世界影響力的的國際化電視臺。縮寫為CBS，美國三大全國性商業(yè)廣播電視網之一。1927年成立?？偛吭O在紐約。1941年，正式開辦電視廣播，1954年，播出彩色電視。1987年在紐約等城市直接經營電視臺5座，中波廣播電臺6座，調頻廣播電臺7座。另有通過合同關系參加該廣播網的電視臺?200多座，形成全國性廣播電視網。

史偉云院長向哥倫比亞電視臺記者介紹生物工程角膜相關情況

?

史偉云院長精湛的手術技術讓從事多年醫(yī)療采訪的哥倫比亞電視臺記者十分驚訝

?

哥倫比亞電視臺記者對已經接受過生物工程角膜移植的患者進行采訪

?

史偉云院長、高華副院長與哥倫比亞電視臺專訪攝制組合影

President Weiyun SHI of Shandong Eye Hospital Accepted an Exclusive Interview with Columbia Broadcasting System

President Weiyun SHI of Shandong Eye Hospital accepted an exclusive interview with Columbia Broadcasting System on the clinical questions about the world’s first bio-engineered cornea approved by SFDA. The broadcasting of the interview named “Scientists working on restoring human sight with pig eyes” on CBS has drawn a great deal of public attention.

President SHI gave a detailed introduction to the clinical application condition of the world’s first bio-engineered cornea approved by SFDA: “The bioengineered corneas are made from xenogeneic corneas through multilevel processing using decellularized special techniques, which remove antigens in corneas like cells, impure protein and polysaccharide and preserve the structure of natural corneal stromal collagens and their transparency. The biocompatibility is good and the biosecurity is high. They can integrate into the surrounding tissue quickly. With transparent transplanted cornea, the visual acuity of patients can be improved quickly. This is an epoch-making high-tech production with complete independent intellectual property rights.”

At the same time, president SHI stressed: “The characteristics of surgical techniques for transplanting artificial biological cornea and donor cornea are obvious. Both the selection of surgical indications and the treatment during perioperative period need unique techniques, so training surgeons for bio-engineered corneal transplantation is an indispensable step in the way to restore sight for patients with corneal blindness.”

Under the guidance of the staff of Shandong Eye Hospital, several members of the interviewing group were allowed to enter the operating room after the disinfection and other procedures to shoot the cornea transplant surgery with tissue engineering cornea by president SHI. The excellent surgical techniques amazed the CBS reporter, who had conduced medical interviews for many years. “Watching the surgery by president SHI is just like watching a wonderful performance.” She praised again and again.

During the interview, president SHI said humorously: “Sometimes CSB is referred to as ‘Eye Network’ as your logo looks like an eye. You see, CBS and ophthalmology are closely connected.” These words made the interview atmosphere more relaxing.

The CBS reporter also interviewed a patient who had received bio-engineered corneal transplantation.

?

Relative information：

The academic team led by Academician Lixin XIE and Professor Weiyun SHI of Shandong Eye Institute and Shandong Eye Hospital is the main technical support power for the world’s first bio-engineered cornea developed by China Regenerative Medicine International Limited. The bio-engineered cornea has obtained the Registration Certificate for Medical Device from CFDA at the end of April, 2015 and was officially put into production and market on May, 23, 2015. As the world's first bio-engineered cornea, it can be widely used in 50% of corneal blind treatment, which can greatly alleviate the clinical situation of low cornea donation rate in China, and bring hope of regaining sight for 4 million corneal blind patients in China and even 60 million all over the world. The world's first bioengineered corneal clinical transplantation conducted at Shandong Eye Institute (Qingdao Eye Institute, Shandong Eye Hospital) in September 2015 was successful.

In view of the great contributions Shandong Eye Institute has made in the research and development of cornea and its leading role in the basic and clinical researches of corneal disease in China, the first doctor training base for bio-engineered corneal transplantation was established at Shandong Eye Hospital. Since July 2016, nearly 300 domestic doctors and over 10 international doctors have been trained here. The training has helped the doctors to establish a deeper understanding towards bio-engineered cornea and has improved doctors’ clinical practical ability and surgical techniques.